Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib hydrochloride
Drug ID BADD_D01688
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 11525740
TTD Drug ID Not Available
NDC Product Code 68578-0015; 53104-7727; 0078-1077; 16436-0125; 63379-093; 54893-0014; 52482-015; 53296-0125; 62207-977; 68554-0058; 0078-0670; 76055-0050; 66499-0055
UNII 33Y9ANM545
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H24ClN7O2S
CAS Registry Number 635702-64-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hepatotoxicity09.01.07.009; 12.03.01.008---
Hypertension24.08.02.001--
Hypothyroidism05.02.03.001; 14.11.01.012--
Infection11.01.08.002---
Insomnia17.15.03.002; 19.02.01.002--
Leukopenia01.02.02.001---
Lymphopenia01.02.02.002---
Mucosal inflammation08.01.06.002---
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nail disorder23.02.05.002--
Nausea07.01.07.001--
Neutropenia01.02.03.004---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Palmar-plantar erythrodysaesthesia syndrome17.02.07.009; 23.03.05.009--
Proteinuria20.02.01.011--
Rash23.03.13.001---
Skin depigmentation23.05.02.002---
Skin disorder23.03.03.007---
Skin hypopigmentation23.05.02.003--
Stomatitis07.05.06.005--
Thrombocytopenia01.08.01.002---
Thrombosis24.01.01.006---
Torsade de pointes02.03.04.005---
Tumour pain16.32.03.003--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Blood phosphorus decreased13.11.01.015---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages